Filing Flows › Comparisons › KNSA vs HRMY
Kiniksa Pharmaceuticals International vs Harmony Biosciences Holdings: KNSA and HRMY compared
Kiniksa Pharmaceuticals International is the larger company: $286M of revenue in its latest quarter (Q3 2026) against $269M for Harmony Biosciences Holdings (Q3 2026). Kiniksa Pharmaceuticals International is growing faster (+58% against +12% a year earlier). Harmony Biosciences Holdings is more profitable, with an operating margin of 20.2% against 19.0%.
Where the money goes: KNSA and HRMY
Kiniksa Pharmaceuticals International (KNSA) · Q3 2026
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Harmony Biosciences Holdings (HRMY) · Q3 2026
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart follows the revenue to costs, profit and cash.
| Kiniksa Pharmaceuticals International (KNSA) | Harmony Biosciences Holdings (HRMY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $286M | $269M |
| Revenue growth, Y/Y | +58% | +12% |
| Gross margin | — | 70.0% |
| Operating margin | 19.0% | 20.2% |
| Net earnings | $47.3M | $48.2M |
| Net margin | 16.6% | 17.9% |
| Operating cash flow | $47.5M | $76.7M |
| Free cash flow | $47.4M | — |
Questions
Which is bigger, Kiniksa Pharmaceuticals International or Harmony Biosciences Holdings?
Kiniksa Pharmaceuticals International is the larger company: $286M of revenue in its latest quarter (Q3 2026) against $269M for Harmony Biosciences Holdings (Q3 2026).
Is Kiniksa Pharmaceuticals International or Harmony Biosciences Holdings growing faster?
Kiniksa Pharmaceuticals International is growing faster (+58% against +12% a year earlier).
Which is more profitable, Kiniksa Pharmaceuticals International or Harmony Biosciences Holdings?
Harmony Biosciences Holdings is more profitable, with an operating margin of 20.2% against 19.0%.
More: Kiniksa Pharmaceuticals International earnings · how Kiniksa Pharmaceuticals International makes money · Harmony Biosciences Holdings earnings · how Harmony Biosciences Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 27, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.